A promising Swiss drug against Covid-19
A Swiss drug against Covid-19 could be on the way, announces Molecular Partners, a company working in partnership with Novartis.
To develop Ensovibep, Molecular Partners used the technology of DARPins, antibody mimetic proteins obtained by genetic engineering. The spin-off developed the technology with support from the Swiss National Science Foundation, including under the National Centre of Competence in Research "Structural Biology", launched in 2001.